Experimental drug combo takes aim at relapsed leukemia

NCT ID NCT04874480

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This early-phase trial tests a new drug called tegavivint, given together with the chemotherapy decitabine, for people whose leukemia has returned or not responded to standard treatments. The main goals are to find the safest dose and to watch for side effects. Only 9 adults with relapsed or refractory acute myeloid leukemia are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tegavivint (BC-2059) combined with decitabine
What this could lead to: If it works, this could point toward a new treatment option for people with leukemia that has come back or stopped responding to other therapies.
What could go wrong: This is a very early (Phase I) trial with only 9 participants, so it is mainly looking at safety and dosing. It may not lead to an effective treatment, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia leukemia refractory hematologic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT LEUKEMIA REFRACTORY LEUKEMIA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.